U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to ...

Additionally, according to heart failure guidelines, endomyocardial biopsy is a class IIa recommendation for assessing HF patients, to be used "when a specific diagnosis is suspected that would ...

The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients ...

Hypertension (HTN) increases the risk of heart failure (HF) and it precedes it in 75 percent of cases. This article reviews essential HTN treatment in patients at risk for developing HF.

Heart failure (HF) is a growing global health concern, affecting more than 64 million people worldwide. It develops when the heart can no longer pump enough blood to meet the body's demands, often due ...

InterShunt Technologies has begun an early feasibility study of its device for reducing symptoms of heart failure.

A scientific statement has been published by the ACC regarding the management of obesity in adults with heart failure.

See how GLP-1 drugs reduce heart and kidney complications in MGUS and diabetes—explore the clinical evidence. Keep reading!

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

There are consistent associations between elevated urinary metal levels and increased HF risk over time across geographically diverse cohorts of adults.

Bayer presents Kerendia data in heart failure with preserved and mildly reduced LVEF at ESC, sparking debate about how it may fit into treatment.

The data indicate it’s worth a shot to try TEER in many with secondary MR, but clinical judgement is critical.